2001 Healthcare Leads Safety 
European Pharmaceutical Review
JANUARY 25, 2024
Within the EU, patient information leaflets (PILs) are not merely a regulatory requirement but a cornerstone of patient safety. They are vital to ensuring the safe and effective use of medicines, making them an integral part of healthcare in Europe. percent as EU average with some Member States as high as 25 percent).
Pharmaceutical Technology
FEBRUARY 20, 2023
On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. Hans Bunschoten: Viroclinics was founded in 2001, spun out of a university setting.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 19, 2022
1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.
European Pharmaceutical Review
JULY 20, 2023
Covered SoHO activities are “action[s], or series of actions, that [have] a direct impact on safety, quality or efficacy of SoHOs.” This may lead to longer development timelines and higher costs for life science companies. This may also require investments in equipment and facilities.
Pharmaceutical Technology
OCTOBER 5, 2008
“In 2001, Japan’s Taisho Pharmaceutical tried to merge with Tanabe, but it failed due to differences in corporate culture.’ Like in many other sectors, China and India are the ones labelled as those which will lead the expansion. The sector is also attracting inbound activity from leading drugs companies.
Expert insights. Personalized for you.
81 
Let's personalize your content